THEMIS-PCI Benefit vs Bleeding Algorithm
Patient bleeding-risk inputs
Enter baseline findings to calculate CRUSADE.
About the algorithm
THEMIS-PCI was a prespecified subgroup analysis in patients with type 2 diabetes, stable coronary artery disease, and previous PCI. Median follow-up was 3.3 years. The primary efficacy outcome was cardiovascular death, myocardial infarction, or stroke.
| Outcome | Ticagrelor + aspirin | Aspirin alone |
|---|---|---|
| CV death, MI, or stroke | 7.3% | 8.6% |
| TIMI major bleeding | 2.0% | 1.1% |
CRUSADE point assignments
CRUSADE predicts in-hospital major bleeding among patients with NSTEMI. Its eight variables are hematocrit, creatinine clearance, heart rate, sex, CHF signs, vascular disease, diabetes, and systolic blood pressure. Age is not a CRUSADE variable and is not scored.
| Variable | Categories and points |
|---|---|
| Hematocrit | <31: 9; 31 to <34: 7; 34 to <37: 3; 37 to <40: 2; ≥40: 0 |
| Creatinine clearance | ≤15: 39; >15–30: 35; >30–60: 28; >60–90: 17; >90–120: 7; >120: 0 |
| Heart rate | ≤70: 0; 71–80: 1; 81–90: 3; 91–100: 6; 101–110: 8; 111–120: 10; >120: 11 |
| Female sex | 8 |
| CHF signs | 7 |
| Peripheral vascular disease or prior stroke | 6 |
| Diabetes | 6 |
| Systolic BP | ≤90: 10; 91–100: 8; 101–120: 5; 121–180: 1; 181–200: 3; >200: 5 |
CRUSADE category rates
| Score | Category | Approximate in-hospital bleeding |
|---|---|---|
| ≤20 | Very low | 3.1% |
| 21–30 | Low | 5.5% |
| 31–40 | Moderate | 8.6% |
| 41–50 | High | 11.9% |
| >50 | Very high | 19.5% |
Interpretation and limitations
Do not conflate the estimates. CRUSADE predicts in-hospital bleeding in NSTEMI; THEMIS-PCI reported longer-term TIMI major bleeding in stable CAD with diabetes and prior PCI. Populations, endpoints, and time horizons differ.
NNT and NNH are reciprocals of rounded absolute differences from the subgroup report. They are approximate, apply to the trial population and follow-up, and are not patient-specific predictions.
Clinical context
- Consider prior bleeding, anemia, renal function, age and frailty, anticoagulation, ischemic risk, prior antiplatelet tolerance, and patient preferences.
- Confirm similarity to the THEMIS-PCI population and consult current guidelines and approved product information.
- Do not use this tool alone to decide whether to start or continue ticagrelor.
References
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.